Skip to main content
Figure 5 | Genome Biology

Figure 5

From: Clinical drug response can be predicted using baseline gene expression levels and in vitrodrug sensitivity in cell lines

Figure 5

Prediction of erlotinib sensitivity in NSCLC patients. (a) Months-to-progression plotted against predicted probability of erlotinib sensitivity. All patients are EGFR wild-type. KRAS mutations are highlighted and a linear regression line is shown. (b) The predicted probability of sensitivity to erlotinib plotted against months-to-progression for individuals treated with sorafenib. NSCLC, non-small cell lung cancer.

Back to article page